Kim Helen Susan
SEC-identified person · CIK 1422772 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Aktis Oncology, Inc. AKTS | Director | filed 2026 - 2026 |
| Prothena Corp plc PRTA | Director | filed 2022 - 2025 |
| Applied Molecular Transport Inc. AMTI | Director | filed 2020 - 2021 |
| Ventrus Biosciences INC VTUS | Director | filed 2018 - 2020 |
| Max-1 Acquisition Corp XCUR | Director | filed 2017 - 2020 |
| Kite Pharma, Inc. KITE | EVP, Business Development | filed 2015 - 2017 |
| Viracta Therapeutics, Inc. VIRX | Director | filed 2009 - 2015 |
| Immunocellular Therapeutics, Ltd. IMUC | Director | filed 2012 - 2014 |
| Kosan Biosciences INC KOSN | Sr VP, Chief Business Officer | filed 2008 - 2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.